SequelSEC

ATOSSA THERAPEUTICS, INC. ATOS

Pharmaceutical Preparations · CIK 0001488039 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2016-09-30
Operating income
-$1.56M
Fiscal year ended 2016-09-30
Free cash flow
Unavailable
Fiscal year ended 2016-09-30

Valuation, from the filing

Public float$107.15MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$12.44Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin-7431.9%0th
Net margin-896491.6%0th
Operating margin-725746.2%0th
R&D / revenue134220.3%99th
Revenue YoY growth-95.6%11th
Current ratio1.72x25th

ATOSSA THERAPEUTICS, INC. (ATOS) reported revenue of $0 and net income of $204.69K for the fiscal year ended 2016-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ATOSSA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ATOSSA THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Revenue$0$0$0$1.76K$0$0$0$2.71K$3.43K$9.88K
Cost of revenueUnavailable$0$0-$3.24M$313.41K$0$0$0$0$0
Gross profitUnavailable$0$0-$2.09M$458.84K$0$0$2.71K$3.43K$9.88K
Operating income-$1.56M-$1.72M-$2.33M-$2.47M-$3.84M-$3.17M-$3.27M-$3.33M-$3.25M-$3.19M
Net income$204.69K-$1.72M-$2.33M-$4.96M-$4.32M-$3.15M-$3.34M-$5.81M-$3.25M-$3.19M
Research & development$85.00K$168.99K$149.97K$471.36K$948.96K$373.47K$565.80K-$746.11K$923.17K$510.77K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income$204.69K-$1.72M-$2.33M-$2.59M-$3.77M-$3.12M-$3.27M-$3.33M-$3.25M-$3.19M
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.47M$1.55M$2.18M$1.64M$2.40M$2.45M$2.36M$1.77M$2.04M$2.46M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ATOSSA THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Cash & equivalents$4.39M$1.19M$2.88M$3.72M$7.84M$11.40M$9.73M$8.50M$11.37M$14.30M
Total assets$6.28M$3.28M$5.10M$6.24M$12.36M$16.56M$13.80M$11.76M$16.77M$19.82M
Current assets$4.56M$1.45M$3.39M$4.29M$9.54M$13.76M$11.37M$9.34M$11.72M$14.67M
Total liabilitiesUnavailableUnavailableUnavailable$2.50M$3.30M$3.44M$3.52M$2.27MUnavailableUnavailable
Current liabilities$863.77K$874.26K$1.33M$2.50M$3.29M$3.41M$3.49M$2.26M$1.54M$1.56M
Total equity incl. NCI$5.41M$2.41M$3.77M$3.74M$9.06M$13.12M$10.28M$9.50M$15.23M$18.26M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable$0$170.86K$101.34K$94.63K$9.28K$45.87K$1.91K
Accounts receivableUnavailableUnavailableUnavailableUnavailable$1.06M$2.01M$1.28M$297.96K$29.15K$48.16K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$0$12.53K$25.23K$49.22KUnavailableUnavailable
Accounts payable$197.35K$282.79K$429.05K$814.45K$1.18M$580.54K$966.21K$513.04K$439.25K$790.18K

Cash flow

ATOSSA THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Operating cash flow$635.50K-$1.66M-$2.99M-$3.95M-$3.48M-$3.52M-$3.00MUnavailableUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$82$79-$5.02K-$177.67K-$29.08K-$15.63K-$66.04KUnavailableUnavailableUnavailable
Financing cash flow$2.56MUnavailableUnavailableUnavailable-$53.86KUnavailableUnavailableUnavailableUnavailableUnavailable
Net change in cash$3.20M-$1.69M-$833.24K-$4.12M-$3.56M$1.67M$1.23M-$2.87M-$2.92M-$2.29M
Stock-based compensation$257.39K$200.19K$192.46K$206.14K$317.99K$205.11K$148.87K$11.17K$147.40K$167.53K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$74.81K$76.84K$75.73K$104.36K$112.97K-$8.95K$64.25K$99.34K$128.05K$127.83K

Derived

ATOSSA THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable-119126.9%UnavailableUnavailableUnavailable100.0%100.0%100.0%
Operating marginUnavailableUnavailableUnavailable-140733.6%UnavailableUnavailableUnavailable-122680.2%-94724.3%-32268.7%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable411.8%UnavailableUnavailable
Current ratio5.28x1.66x2.55x1.72x2.90x4.03x3.26x4.13x7.61x9.39x
Revenue YoY growthUnavailableUnavailableUnavailable-35.2%-100.0%-100.0%-100.0%UnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable-282229.6%UnavailableUnavailableUnavailable-214265.5%-94728.4%-32283.3%
R&D / revenueUnavailableUnavailableUnavailable26812.1%UnavailableUnavailableUnavailable-27501.3%26946.0%5172.3%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable0.00x0.00x0.00xUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATOS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.